TAYSHA GENE THERAPIES INC (TSHA:NASDAQ)
$4.49 -0.14 (-3.0238%)
Analysed TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) News Sources
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment
06-04-2026
yahoo.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03-04-2026
yahoo.com
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
22-03-2026
fool.com
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story
21-03-2026
yahoo.com
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
19-03-2026
yahoo.com
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary
19-03-2026
moby.co
Taysha Gene Therapies Q4 Earnings Call Highlights
19-03-2026
marketbeat.com
Taysha (TSHA) Q4 2025 Earnings Call Transcript
19-03-2026
fool.com
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
19-03-2026
yahoo.com
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect
18-03-2026
yahoo.com
What is the current price of TAYSHA GENE THERAPIES INC (TSHA:NASDAQ)?
The current price of TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) is $4.49.
TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) absolute price change since previous trading day?
The absolute price change of TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) since the previous trading day is $-0.14.
TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) percentage price change since previous trading day?
The percentage price change of TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) since the previous trading day is -3.0238%.
What is the most recent average sentiment score for TAYSHA GENE THERAPIES INC (TSHA:NASDAQ)?
The most recent average sentiment score for TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for TAYSHA GENE THERAPIES INC (TSHA:NASDAQ)?
The most recent sentiment for TAYSHA GENE THERAPIES INC (TSHA:NASDAQ) is .
SEC-8K** Filing Available For TAYSHA GENE THERAPIES INC (TSHA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.